Table 2 The cumulative incidences of severity of hearing loss by type of aminoglycoside in the MDR-TB drug regimen
| Severity of hearing loss | Amikacin group (n = 51) | Cumulative incidence | Kanamycin group (n = 302) | Cumulative incidence | Total cases (N = 353) | Cumulative incidence |
|---|---|---|---|---|---|---|
| Mild | 5 | 10 % | 60 | 20 % | 65 | 18 % |
| Moderate | 7 | 14 % | 41 | 14 % | 48 | 14 % |
| Moderate-Severe | 6 | 12 % | 27 | 9 % | 33 | 9 % |
| Severe | 5 | 10 % | 16 | 5 % | 21 | 6 % |
| Profound | 11 | 22 % | 21 | 7 % | 32 | 9 % |
| Missing severity grading | 4 | 8 % | 3 | 1 % | 7 | 2 % |
| Total cases | 38 | 75 % | 168 | 56 % | 206 | 58 % |